leadf
logo-loader
viewCanntab Therapeutics Ltd

Canntab awarded Health Canada cannabis research licence

It marks the final step to obtain a standard processing licence and sale for medical purposes licence

Canntab Therapeutics Ltd - Canntab awarded Health Canada cannabis research licence
Canntab’s facility in Markham, Ontario, is equipped to accommodate all manufacturing necessary to produce its pharmaceutical-grade cannabis hard pill formulations

Canntab Therapeutics Limited (CSE:PILL) (OTCMKTS:CTABF) revealed Monday that Health Canada has granted it a cannabis research licence for continuing the research and development of its pharmaceutical-grade cannabis hard pill formulations at its Markham Ontario facility. 

In a statement, the Canadian company said that after getting a standard processing licence and sale for medical purposes licence from Health Canada, Canntab will begin full-scale manufacturing of its suite of precision oral dose products.

The firm is a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application. The company's hard pill oral delivery formulations encapsulate extended-release, instant release, and bi-layered hard pills which offer patients and practitioners accurate dosing.

READ: Canntab Therapeutics submits Site Evidence Package to Health Canada for Licence Producer Status approval

The additional licences will enable Canntab to submit a notice of new cannabis products (NNCP) to Health Canada, said the company.

Jeff Renwick, co-founder and CEO of Canntab said the just granted cannabis research licence will allow the company to prepare for when it receives its standard processing licence and sale for medical purposes licence, which are likely to come through “shortly.”

“Once we obtain our Standard Processing Licence and Sale for Medical Purposes Licence, we will have products ready for distribution and sale,” said Renwick.

"Our facility is fully built-out and we are excited to prepare our final formulations for submission. We are equally excited with the prospect of continuing R&D in full force at our Markham facility, beginning with our proprietary oral dissolvable Tablet formulations which enter through the buccal cavity in the patient's mouth," he added.

Canntab’s facility, located in Markham, Ontario, is designed and fully equipped to accommodate all manufacturing necessary to produce Canntab's pharmaceutical-grade cannabis hard pill formulations (solid oral dosage forms), which the company believes is the future of medical cannabis.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

Quick facts: Canntab Therapeutics Ltd

Price: 0.67 CAD

CSE:PILL
Market: CSE
Market Cap: $22.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Canntab Therapeutics received purchase order from Australia while also...

Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive Vancouver with news the company has announced the launch of its suite of hard pill cannabinoid formulations in Australia with its partner CANN Global Ltd. Goldstein takes Proactive through...

on 26/10/20

2 min read